CDSCO Issues Circular on Sale of IVF Media and Reagents to ART Registered Centres Only
The Central Drugs Standard Control Organisation (CDSCO) has issued an important circular regarding the sale and distribution of In-Vitro Fertilization (IVF) media, reagents, cryopreservation media, and related consumables used in Assisted Reproductive Technology (ART) procedures. The circular, issued by the Medical Devices Division of CDSCO, highlights that these products are regulated under the Medical Devices Rules, 2017, and should only be supplied to healthcare facilities registered under the Assisted Reproductive Technology (Regulation) Act, 2021 and the Surrogacy (Regulation) Act, 2021. This step aims to strengthen regulatory oversight, ensure patient safety, and maintain ethical standards in fertility treatment services across India.
Why Has CDSCO Issued This Circular?
CDSCO issued the circular after receiving reports that IVF media and related consumables were being supplied to healthcare facilities that are not registered under the applicable ART and Surrogacy regulations. The authority observed that the use of these sensitive medical products by unauthorized facilities could pose significant risks to patient health and compromise the ethical delivery of reproductive healthcare services.
To address these concerns, CDSCO has advised all stakeholders to ensure that such products are supplied only to legally registered ART clinics and ART banks.
IVF Media and Reagents Are Regulated Medical Devices
The circular reiterates that IVF media, cryopreservation media, reagents, and other related consumables are covered under the Medical Devices Rules, 2017. Since these products directly influence the quality, safety, and effectiveness of fertility treatments, manufacturers and importers must obtain the required licenses before manufacturing, importing, or selling them in India.
Compliance with the Medical Devices Rules ensures that these products meet prescribed standards for quality, safety, and performance before reaching healthcare providers.
Supply Restricted to Registered ART Clinics and ART Banks
According to CDSCO, IVF-related medical devices should be supplied only to healthcare facilities that are registered under -
- Assisted Reproductive Technology (Regulation) Act, 2021
- Surrogacy (Regulation) Act, 2021
These laws regulate the operation of fertility clinics, ART banks, and surrogacy services to ensure ethical practices, transparency, and patient protection. By restricting the supply of IVF consumables to registered centres, the government aims to eliminate unauthorized use and strengthen accountability within the reproductive healthcare sector.
Responsibilities of Manufacturers, Importers and Distributors
The circular places responsibility on all stakeholders involved in the supply chain, including manufacturers, importers, distributors, dealers, and suppliers. Before supplying IVF media and related consumables, businesses should verify that the purchasing clinic or ART bank is officially registered under the applicable laws.
Maintaining proper documentation, verifying customer registration, and ensuring traceable distribution practices are essential steps to demonstrate regulatory compliance and avoid legal consequences.
Importance of Compliance for the IVF Industry
The latest CDSCO circular reinforces the importance of compliance throughout the medical device supply chain. Organizations dealing with IVF media and reagents should establish strong internal procedures to ensure that products are distributed only to authorized healthcare facilities.
Failure to comply with the Medical Devices Rules, 2017, or the provisions of the ART and Surrogacy Acts may lead to regulatory action. Therefore, manufacturers and distributors should regularly review their compliance systems and maintain updated records of their customers and product distribution activities.
Impact on India's Reproductive Healthcare Sector
The circular is expected to improve patient safety by preventing unauthorized facilities from accessing IVF media and related consumables. It also promotes ethical reproductive healthcare by ensuring that fertility treatments are carried out only by legally authorized clinics operating under a regulated framework.
This initiative strengthens the government's efforts to improve the quality and transparency of assisted reproductive technology services while ensuring that medical devices used in fertility treatments are handled responsibly throughout the supply chain.
Conclusion
The CDSCO circular serves as an important compliance reminder for manufacturers, importers, distributors, and healthcare providers involved in the IVF sector. By directing stakeholders to supply IVF media, reagents, cryopreservation media, and related consumables only to registered ART clinics and ART banks, the authority aims to protect patient safety, support ethical medical practices, and strengthen regulatory compliance under the Medical Devices Rules, 2017, the ART (Regulation) Act, 2021, and the Surrogacy (Regulation) Act, 2021. Stakeholders should review their distribution processes and ensure strict adherence to these regulatory requirements to avoid compliance issues and contribute to a safer reproductive healthcare ecosystem in India.